DCAL Dishman Carbogen Amcis Q4 FY25 results (Jan–Mar 2025) and concall
Dishman Carbogen Amcis reported a strong Q4 FY25, marking the third consecutive quarter of improving performance, driven by robust growth in its CRAMS segments and effective cost control measures. The company achieved a 17.4% EBITDA margin for FY25 and 21.4% for Q4, exceeding expectations. Strategic operational milestones, including the full operationalization of the French facility and regulatory approvals in China, are expected to fuel future growth and margin expansion, with a target of 12-15% CAGR and 20% EBITDA margin for FY26.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 93 | 97 | 106 |
| EBITDA | 13 | 23 | 21 |
| Net profit | 14 | -13 | -7 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
